It has been shown that targeting PCNA with an APIM-peptide impaired cellular defense mechanisms and major signaling pathways, with the consequence of hypersensitivity of cancer cells to chemotherapies in vitro and in vivo [13, 21, 22]. This evidence concerns the gene PCNA and cancer.